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JLME COLUMN
The Ethical Health Lawyer
Watch Out for
Whistleblowers
Leslie Griffin
About this Column
The Ethical Health Lawyer is edited by
Joan H. Krause and Richard S. Saver.
Joan H. Krause is Associate Professor
of Law at the University of Houston
Law Center and Co-Director of the
University of Houston Health Law &
Policy Institute. Richard S. Saver is
Assistant Professor of Law at the Uni-
versity of Houston Health Law & Policy
Institute.
"There's a new whistleblower in
Washington," according to CNN
News. He is Food and Drug Admin-
istration scientist David Graham,
who claims that the FDA failed to
warn the public about certain drugs'
dangerous side effects and pres-
sured him to change his research's
conclusion that the arthritis drug
Vioxx caused heart attacks.2 Another
Washington whistleblower, Dr.
Jonathan Fishbein of the National
Institutes of Health, alleged that he
was fired because "he had raised con-
cerns about sloppy practices that
might endanger patient safety" in a
study of the AIDS drug nevirapine.3
Graham and Fishbein thus joined
the ranks of whistleblowers who
have gained some prominence in re-
cent years for their reporting of cor-
porate or institutional misconduct.
The best-known whistleblowers-
the FBI's Coleen Rowley, Enron's
Sherron Watkins, and WorldCom's
Cynthia Cooper, who together re-
ceived Time magazine's Whistle-
blower Person of the Year Award in
20024 - focused public attention on
the reform of corporate accounting
and legal practices. The Graham
and Fishbein examples, however,
provide a timely reminder to the
ethical health lawyer to be prepared
for whistleblowers. State and fed-
eral law's treatment of health care
whistleblowers is comprehensive
and complex. Wise health lawyers
will anticipate the whistleblowers in
their midst and establish appropriate
programs and procedures to prevent
both misconduct and retaliation long
before the whistleblower's story ap-
pears on CNN.
Retaliation Against
Whistleblowers
Whistleblowers are individuals who
report misconduct; they frequently
face retaliation for doing so. Impor-
tant legal questions about retaliation
arise whenever an employee who re-
ports misconduct is fired or de-
moted. Unfortunately, this law of
wrongful or retaliatory discharge is
a mess: "piecemeal," "patchwork,"
"hodgepodge."5 The general rule is
at-will employment, namely that an
employee may be fired at the em-
ployer's will without recourse for
job termination or demotion. State
courts and legislatures, however,
have enacted numerous exceptions
to this rule, offering remedies to, for
example, government (but not pri-
vate company) whistleblowers,
whistleblowers whose reporting in-
volves important questions of public
policy or safety, or whistleblowers
who refuse to perform an illegal
activity.6 In federal law, the False
Claims Act, which lets private parties
who discover federal health care pro-
gram fraud file qui tam suits on the
government's behalf and receive a
percentage of the government's pro-
ceeds, also protects against individ-
uals being "discharged, demoted,
suspended, threatened, harassed, or
in any other manner discriminated
against" for participating in the fraud
investigations. 7 Some combination
of damages such as reinstatement,
back pay, costs and attorney's fees is
available under these federal and
state standards.
Thus step one for the ethical
health lawyer is to understand the
numerous laws that govern retalia-
tion against whistleblowers in the
jurisdiction. Several federal statutes
are directed explicitly at medical
whistleblowers.8 Moreover, even
states whose courts disfavor private
whistleblower lawsuits may have leg-
islation that affords special protec-
tion to medical care facility employ-
ees.9
Once the universe of whistle-
blower law is identified, the scope
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of protection against retaliation
remains contested. In Dr. Fishbein's
NIH case, for example, the United
States Merit Systems Protection
Board ruled recently that the
Whistleblower Protection Act did
not protect the doctor because he
was a probationary, "Title 42" em-
ployee to whom the provisions of the
act did not apply.10 The United States
Supreme Court is also examining the
range of whistleblower protection
this term. In a non-medical case,
Roderick Jackson, the male coach of
a girls' high school basketball team,
allegedly lost his coaching job after
reporting that the girls' team did not
receive equal funding or access. Jack-
son filed suit for retaliation under
Title IX, the federal legislation that
prohibits sex discrimination in edu-
cation, but the Eleventh Circuit dis-
missed his lawsuit on the grounds
that Title IX does not provide a pri-
vate right of action for whistleblow-
ers who report gender discrimina-
tion but are not subjected to it
personally." The Jackson decision
may clarify the protection afforded
to whistleblowers under numerous
federal statutes; it also raises anew
the recurring issues of at-will em-
ployment and statutory protection
against retaliation. Piecemeal, patch-
work, hodgepodge, developing, un-
certain - the specific law of retalia-
tory discharge requires careful study.
Reporting Misconduct
by Whistleblowers
Journalistic and literary descriptions
of whistleblowers often focus on the
moral and personal factors that per-
suade them to risk their careers and
report misconduct. Reporting also
poses equal challenges for the health
lawyer. Over the last three years, cor-
porate lawyers have been forced to
recognize that retaliation lawsuits
are not their only worry about
whistleblowers. After Enron and
other corporate scandals, Congress
passed the Sarbanes-Oxley Act,
which, in addition to prohibiting re-
taliation against whistleblowers, re-
quires publicly traded companies to
set up internal mechanisms that
allow employees to report miscon-
duct and establishes criminal penal-
REGULATION OF BIOBANKS * SPRING 2005
ties for employers if retaliation oc-
curs. 12 Although Sarbanes-Oxley ap-
plies only to publicly traded compa-
nies, its treatment of whistleblowers
provides a model of "best practices"
for other industries, including pri-
vate and non-profit health care or-
ganizations.
1 3
In addition to the Act's protection
of employees against retaliation, the
two other whistleblower provisions
hundreds of doctors to prescribe
Neurontin for non-approved uses."'17
Accountants Jim Alderson and
John Schilling detected fraudulent
Medicare reimbursements at Co-
lumbia/HCA and cooperated with
the government to uncover the
fraud.' Franklin received a $26.6
million settlement from Pfizer, while
Alderson and Schilling split $100
million. 19
State and federal law treatment of health care
whistleblowers is comprehensive and complex.
Wise health lawyers will anticipate the
whistleblowers in their midst and establish
appropriate programs and procedures to prevent
both misconduct and retaliation long before the
whistleblower's story appears on CNN.
named above are noteworthy. First,
like corporate lawyers, health
lawyers should establish procedures
that give employees the occasion to
report wrongdoing without fear of
reprisal and employers the opportu-
nity to cure misconduct. Because
Sarbanes-Oxley did not specify those
procedures, lawyers must consider
carefully what reporting mecha-
nisms - internal or external, anony-
mous or non-anonymous - will be
most effective.14 Second, Sarbanes-
Oxley's criminalization of retaliation
against whistleblowers "represents
a momentous departure from the
state statutes, as well as the Model
[Whistleblower] Act."'5 Those crim-
inal sanctions are not limited to pub-
licly traded companies, but "seem-
ingly encompass every employer."'16
The securities legislation thus raises
the question whether criminal sanc-
tions for employers will grow in im-
portance as a means to police insti-
tutional misconduct and punish
retaliation in every industry.
There have been numerous
whistleblowers in the health care
industry. In addition to Graham
and Fishbein, for example, David
Franklin reported that Pfizer mar-
keted the epilepsy drug Neurontin
for non-FDA approved purposes
and "gave financial incentives to
Not all whistleblowers are so suc-
cessful. Sometimes they are mis-
taken, and even when they are cor-
rect they can be "quirky, anxious and
irritable."2° Indeed, a leading book
on whistleblowers profiles them as
"psychological narcissists" 21; in sim-
pler language, they can be just the
kind of person everyone wants to
avoid. Nonetheless, the ethical
health lawyer must listen to the
whistle and then ensure that the
whistleblower's complaint is re-
ported, recorded and rectified while
the whistleblower's person never
faces retaliation.
Avoiding settlements or litigation,
and complying with Sarbanes-Oxley,
however, are not the only reasons for
ethical health lawyers to heed the
whistleblower; in this field, the
whistleblower may warn of serious
dangers to life and health. In learn-
ing about such risks, the lawyer
comes face to face with the whistle-
blower's dilemma, namely whether
to report the harm or to decide that
loyalty to clients requires that
lawyers never blow the whistle.
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